12.08.2021 • NewsDiversey

Diversey Buys Tasman Chemicals

Diversey Holdings, a US-headquartered provider of hygiene, infection prevention and cleaning products, has entered into an agreement to buy Australia’s Tasman Chemicals. Financial terms were not revealed. Headquartered in Melbourne, Tasman manufactures professional hygiene and cleaning products to the institutional and food & beverage sectors.

Tasman’s manufacturing infrastructure, in particular, “provides exciting opportunities to integrate our business and expand our product offering,” Diversey said. CEO Phil Wieland noted that the acquisition “provides us with a strong manufacturing footprint, allowing for greater operational flexibility and responsiveness to customer requirements. In addition, “the strong reputation of Tasman will enable us to grow our position in the Australia and New Zealand markets.”

Diversey did not say when it expects the transaction to close.

The Tasman buy follows Diversy’s takeover of Poland’s SaneChem last December, which the company said cements its market-leading position in the Polish market while also strengthening its growth plans for eastern Europe in the core food & beverage markets of brewing, beverage, processed food, dairy, agriculture and pharmaceuticals.

Author: Elaine Burridge, Freelance Journalist

US-based Diversey Holdings has entered into an agreement to buy Australia’s...
US-based Diversey Holdings has entered into an agreement to buy Australia’s Tasman Chemicals for an undisclosed sum. Headquartered in Melbourne, Tasman manufactures professional hygiene and cleaning products to the institutional and food & beverage sectors. (c) Tasman Chemicals

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.